ANI Pharmaceuticals (ANIP.US) announced that it will acquire Alimera Sciences (ALIM.US) for $5.50 per share in cash. The acquisition price is about 75% higher than its closing price of $3.15 last Friday, meaning the valuation of the company is $381 million. Boosted by this news, Alimera Sciences pre-market trading on Monday surged more than 76% at the time of publication.

ANI Pharmaceuticals stated that this acquisition will further promote its rare disease business, and it is expected that this transaction will achieve high single-digit to low double-digit growth in adjusted NON-GAAP earnings per share by 2025 and achieve substantial growth thereafter. The transaction is expected to bring in adjusted NON-GAAP core profits of $35-38 million in 2025, including about $10 million in identified cost synergy effects. ANI Pharmaceuticals plans to finance the transaction through a combination of cash on hand and debt financing.

According to reports, ANI Pharmaceuticals develops, manufactures, and sells generic drugs. Some of the company's generic products include erythromycin ethylsuccinate, methyltestosterone estradiol, idursulfase, levofloxacin, hydrocortisone acetate enema, and vancomycin. Alimera Sciences is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME).